Please assess the completion status of the following clinical trial:

Trial Title: Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* B-cell, CD20+ NHL~* Evidence of engraftment post-autologous peripheral blood stem cell transplant (PBSC-T), aka autologous stem cell transplant (ASCT)~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1~* Creatinine \< 2 mg/dL~* Bilirubin \< 2.0 mg/dL~* Liver function tests (LFTs) \< 5 x upper limit of normal (ULN)~Exclusion Criteria:~* Graft source from bone marrow~* Non-responders \[progressive disease (PD) or stable disease (SD)\] to prior anti-CD20 therapy~* PD after ASCT~* Post-ASCT radiotherapy~* Concomitant treatment with radiotherapy, chemotherapy or immunotherapy including rituximab~* Evidence of active pneumonitis~* Evidence of active infection~* Concurrent prednisone or other systemic steroid medication~* Nitrosourea therapy within 6 weeks of the first treatment with rituximab~* Presence of anti-murine antibody (HAMA) reactivity

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab after ASCT (Type: EXPERIMENTAL): Rituximab 375 mg/m2 starting 6 weeks after ASCT transplant, and for the 5th and subsequent subjects, a second course at the same dose 6 months after ASCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).